| scholarly article | Q13442814 |
| P2093 | author name string | Espen Stang | |
| Vibeke Bertelsen | |||
| P2860 | cites work | Characterization of a novel tripartite nuclear localization sequence in the EGFR family. | Q50698452 |
| Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes. | Q53135719 | ||
| Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. | Q54483949 | ||
| Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects | Q73075684 | ||
| Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization | Q84191383 | ||
| Keeping EGFR signaling in check: ubiquitin is the guardian | Q42366663 | ||
| Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation | Q42800575 | ||
| All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired | Q42816057 | ||
| ERBB2 is a target for USP8-mediated deubiquitination | Q42818688 | ||
| Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. | Q42832682 | ||
| Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies | Q42917525 | ||
| Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking | Q43275675 | ||
| Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin | Q43636937 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. | Q44177173 | ||
| Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. | Q44305765 | ||
| Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. | Q46413205 | ||
| Extracellular HSP90: conquering the cell surface | Q46602835 | ||
| Identification of the domain in ErbB2 that restricts ligand-induced degradation | Q46768014 | ||
| The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner | Q47996210 | ||
| Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression | Q24292840 | ||
| An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 | ||
| Threshold-controlled ubiquitination of the EGFR directs receptor fate | Q24296784 | ||
| Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor | Q24297204 | ||
| Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3 | Q24301306 | ||
| Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor | Q24314620 | ||
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 | ||
| Receptor tyrosine kinases in the nucleus | Q26830216 | ||
| Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally | Q26991472 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 | Q28143497 | ||
| The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| ErbB2 degradation mediated by the co-chaperone protein CHIP | Q28208008 | ||
| Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells | Q28235640 | ||
| Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2 | Q28283279 | ||
| Targeting the dynamic HSP90 complex in cancer | Q28288602 | ||
| HSP90 at the hub of protein homeostasis: emerging mechanistic insights | Q29616824 | ||
| Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pits | Q30159982 | ||
| Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells | Q30439237 | ||
| Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. | Q30479942 | ||
| Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin | Q30839490 | ||
| The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments | Q31107044 | ||
| Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. | Q33468432 | ||
| E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells | Q33606911 | ||
| ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. | Q33820676 | ||
| Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy | Q33837881 | ||
| Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains | Q33841378 | ||
| Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor | Q33886791 | ||
| COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport | Q34109724 | ||
| Molecular mechanisms underlying ErbB2/HER2 action in breast cancer | Q34130548 | ||
| Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation | Q34166390 | ||
| Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu | Q34190181 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands | Q34331822 | ||
| The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus | Q34352437 | ||
| Cargo recognition in clathrin-mediated endocytosis | Q34382206 | ||
| Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion | Q34388870 | ||
| Mechanism of action of trastuzumab and scientific update | Q34437163 | ||
| Reorienting the Fab domains of trastuzumab results in potent HER2 activators | Q34532338 | ||
| Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers | Q34616517 | ||
| Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth | Q34669979 | ||
| Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. | Q34767641 | ||
| Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum | Q35096647 | ||
| Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | Q35566231 | ||
| Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 | ||
| Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent | Q40003014 | ||
| Controlled internalization of Her-2/ neu receptors by cross-linking for targeted delivery | Q40036475 | ||
| A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. | Q40040751 | ||
| Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. | Q40301251 | ||
| Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. | Q40340333 | ||
| Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. | Q40473008 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation | Q40679010 | ||
| Nuclear localization of EGF receptor and its potential new role as a transcription factor | Q40782527 | ||
| Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. | Q40798689 | ||
| Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. | Q40866492 | ||
| The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. | Q41518562 | ||
| Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2 | Q41661332 | ||
| Peptide level immunoaffinity enrichment enhances ubiquitination site identification on individual proteins | Q41848488 | ||
| Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity | Q35641650 | ||
| Secreted heat shock protein-90 (Hsp90) in wound healing and cancer | Q35696767 | ||
| Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. | Q35956440 | ||
| A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors | Q36010772 | ||
| Hsp90 and Cdc37 -- a chaperone cancer conspiracy. | Q36015525 | ||
| Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family | Q36162605 | ||
| p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor | Q36767887 | ||
| Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. | Q36815518 | ||
| Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis | Q36889343 | ||
| Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer | Q37089778 | ||
| Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis | Q37117664 | ||
| Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab | Q37148772 | ||
| Targeting the oncogene and kinome chaperone CDC37. | Q37177064 | ||
| Hsp90, an unlikely ally in the war on cancer | Q37274497 | ||
| Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors | Q37332545 | ||
| Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase | Q37453413 | ||
| Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells | Q37565022 | ||
| HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. | Q37872909 | ||
| Truncated HER2: implications for HER2-targeted therapeutics | Q37894315 | ||
| The role of ubiquitylation in receptor endocytosis and endosomal sorting | Q37987408 | ||
| Antibody-based immunotherapy of cancer | Q37994278 | ||
| Cargo trafficking between endosomes and the trans-Golgi network. | Q38121411 | ||
| Association with membrane protrusions makes ErbB2 an internalization-resistant receptor | Q38345553 | ||
| Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation | Q38669920 | ||
| Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins | Q38725015 | ||
| Analysis of conformational determinants underlying HSP90-kinase interaction | Q39127414 | ||
| Flotillins as regulators of ErbB2 levels in breast cancer | Q39301423 | ||
| Regulated intramembrane cleavage of the EGF receptor | Q39359395 | ||
| Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway | Q39494243 | ||
| Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells | Q39570673 | ||
| Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth | Q39675983 | ||
| HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion | Q39705209 | ||
| Differential effects of EGFR ligands on endocytic sorting of the receptor. | Q39837288 | ||
| The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane | Q39848000 | ||
| Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. | Q39856870 | ||
| Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning | Q39889816 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 424-446 | |
| P577 | publication date | 2014-08-06 | |
| P1433 | published in | Membranes | Q27724032 |
| P1476 | title | The Mysterious Ways of ErbB2/HER2 Trafficking | |
| P478 | volume | 4 |
| Q37251593 | A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. |
| Q53089288 | Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells. |
| Q47111722 | Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies |
| Q38967404 | AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. |
| Q51646294 | Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. |
| Q89078193 | CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer |
| Q59795879 | Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy |
| Q42693739 | Challenges for Super-Resolution Localization Microscopy and Biomolecular Fluorescent Nano-Probing in Cancer Research |
| Q58112887 | Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer |
| Q90269095 | Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models |
| Q35623397 | Dissecting the calcium-induced differentiation of human primary keratinocytes stem cells by integrative and structural network analyses |
| Q57063810 | ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea |
| Q38729111 | ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology |
| Q91980872 | Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
| Q48036929 | Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells |
| Q36331808 | HER2 signaling regulates HER2 localization and membrane retention |
| Q35926284 | Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family |
| Q44347751 | Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization |
| Q41773399 | Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells |
| Q93335769 | Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells |
| Q33621028 | Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. |
| Q35724081 | Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain |
| Q38695293 | Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers |
| Q37690877 | Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. |
| Q93086999 | Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line |
| Q47102400 | Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix |
| Q26773754 | Non-canonical signaling mode of the epidermal growth factor receptor family |
| Q49909762 | Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer |
| Q37662229 | Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. |
| Q36498165 | PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer |
| Q58803127 | Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer |
| Q58601833 | Prognostic value of ErbB2/HER2 in human meningiomas |
| Q64891425 | Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. |
| Q90886367 | Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation |
| Q36113481 | Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases |
| Q36427101 | Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes. |
| Q26745419 | Regulating Axonal Responses to Injury: The Intersection between Signaling Pathways Involved in Axon Myelination and The Inhibition of Axon Regeneration |
| Q37295377 | Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins |
| Q88342631 | Roles of progesterone receptor membrane component 1 and membrane progestin receptor alpha in regulation of zebrafish oocyte maturation |
| Q64289807 | SORLA regulates endosomal trafficking and oncogenic fitness of HER2 |
| Q54112592 | ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling. |
| Q38780521 | Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells |
| Q55317203 | Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells. |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q28073335 | The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family |
| Q64062256 | The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2 breast cancer cells |
| Q93196147 | The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer |
| Q38714954 | The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2. |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q36782465 | p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy |
Search more.